Therapeutic Effect Of Cold And Hot Ablation On Advanced Lung Cancer And The Effect Of Immune Response

ObjectiveTo compare the short-term efficacy,complications and long-term survival rate of argon-helium cryoablation and radiofrequency ablation in the treatment of advanced lung cancer,and to compare the effects of two ablation methods on the immune response of the body,and provide a basis for the minimally invasive treatment of lung cancer.MethodsA retrospective analysis of 92 patients with advanced lung cancer who underwent AHC or RFA treatment in the Imaging and Nuclear Medicine wards of the First Affiliated Hospital of Zhengzhou University from September 2014 to March2016,including 43 patients in the AHC group.49 patients in the RFA group.The basic data of tumor size,clinical stage,combined treatment history and tumor number were analyzed in a balanced manner.The short-term efficacy,complications,bloodimmune function index,local tumor control rate,disease-free progression,and survival rate of the two groups were compared.ResultIn this research,92 patients with lung cancer underwent AHC or RFA,including43 in the AHC group and 49 in the RFA group.The surgery was successfully completed.The postoperative follow-up period was 3-50 months,and the median follow-up time was 24 months.The basic data of the two groups were analyzed and there was no statistical difference.The short-term efficacy was based on the local efficacy at 6 months after surgery as an indicator.There was no significant difference in local efficacy between the two groups.Postoperative complications were mainly pneumothorax,followed by intrapulmonary hemorrhage and pleural reaction.The postoperative complications of AHC group and RFA group were similar,and there was no statistical difference between the two groups.In terms of long-term efficacy,the local control rates of AHC group were 86.05%,41.87%,and 16.28% at 1 year,2years and 3 years,respectively.The local control rate of 1 year,2 years,and 3 years in the RFA group was 75.51%,40.82% and 18.37%.respectively.There were no significant differences in local control rates between the two groups.In the AHC group,the PFS was 23.35 ± 8.67 months and the median PFS was 22 months.In the RFA group,the postoperative PFS was 20.02 ± 7.20 months,and the median PFS was20 months,but there was no statistical difference in PFS between the two groups.Multivariate analysis showed that combination therapy was the only factor affecting PFS.In the AHC group,the 1-,2-,and 3-year survival rates were 90.70%,67.44%and 27.91%,respectively.In the RFA group,the 1-,2-,and 3-year survival rates were87.75%,55.10% and 22.45,respectively,the survival rate of the AHC group was higher than that of the RFA group,but there was no statistical difference between the two groups.The effects of cold or thermal ablation on immune response were significantly higher in the AHC group and the RFA group than in the group before treatment.The changes before and after treatment were statistically different.Therewas no significant difference before and after treatment with CD4+/CD8+.Variety.There were no significant changes before and after treatment with CD3+,CD4+,CD8+ and CD4+/CD8+.Conclusion1.Therapeutic effect of hot and cold ablation for advanced lung cancer is clear,the complications are few,and the long-term curative effect is exact,but there is no significant difference between the two.Combination therapy is the only factor affecting PFS.2.Hot and cold ablation for the treatment of advanced lung cancer can improve the body’s immune function,but there is no significant difference between the two.